Menu
Annual · values20252024202320222021
Operating Cash Flow-43.44 M USD-41.40 M USD-52.40 M USD-34.90 M USD-34.63 M USD
Depreciation & Amortization3.64 M USD3.84 M USD3.40 M USD1.40 M USD769000 USD
Stock-Based Compensation5.71 M USD1.75 M USD9.67 M USD16.39 M USD2.29 M USD
Capital Expenditures196000 USD26000 USD12.04 M USD41.37 M USD5.54 M USD
Cash Flow from Investing-184000 USD34000 USD30.08 M USD-81.96 M USD-5.54 M USD
Cash Flow from Financing11.76 M USD53.73 M USD779000 USD118.55 M USD68.44 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-43.64 M USD-41.42 M USD-64.43 M USD-76.27 M USD-40.18 M USD

Senti Biosciences Inc. is a pioneering biotechnology company focused on the development of next-generation cell and gene therapies. Leveraging synthetic biology, the company engineers novel therapies aimed at treating a range of complex diseases, particularly those within oncology. Senti Biosciences is dedicated to advancing medicines that have the potential to fundamentally change treatment paradigms by enhancing efficacy, safety, and precision. The company's approach involves designing and optimizing genetic circuits that embody sophisticated decision-making paths, allowing therapies to efficiently target and modify disease cells. Its innovative technology platform underscores a commitment to unlocking new therapeutic possibilities and improving patient outcomes. Senti Biosciences plays a crucial role in the biomedical sector by accelerating the development of customizable and intelligent therapeutics, thus contributing to the dynamic and transformative landscape of healthcare solutions.